Drugs / Haemophilus b Conjugate Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04865497 | Jan → Dec 2019 | shigellosis | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03691610 Background | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| — | NCT00034086 Background | ? → Jun 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Haemophilus b Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03691610 ↗ |
| Modality | Vaccine | “haemophilus b conjugate (HIB) vaccine” NCT00034086 ↗ |
| Route | Intramuscular | “Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.” NCT04865497 ↗ |